首页 News 正文

Earning too much! US Senators indirectly pressure Novo Nordisk to lower the price of weight loss pills

王俊杰2017
227 0 0

On Monday local time, US Senator Bernie Sanders wrote a letter to Politburo, one of the largest newspapers in Nordic countries, urging Denmark to pressure the well-known pharmaceutical company Novo Nordisk to lower drug prices.
In the letter, the chairman of the US Senate Health, Education, Labor, and Pensions Committee called on Danes to pressure Novo Nordisk to significantly reduce the "outrageously high prices" of GLP-1 drugs such as Wegovy and Ozempic.
Sanders himself strongly demanded a price reduction from Novo Nordisk and raised a series of cost and manufacturing issues with the pharmaceutical company.
Sanders expressed admiration for Denmark's welfare system and pointed out that Novo Nordisk charges Ozempic about ten times more in the United States than in European countries. "Please help the American people deal with the health crises we face, such as obesity and diabetes."
Unable to afford it
It is reported that in the US market, the price of a single box of Ozempic, a diabetes treatment drug, is close to $969 this year (up 3.5% from last year), while the price of Wegovy, a weight loss drug, is $1349.
A survey released last week by the Kaiser Family Foundation, a non-profit organization in the United States, showed that approximately one eighth of American adults have taken GLP-1 drugs to treat weight loss and related illnesses.
The survey also shows that these drugs are becoming increasingly popular, and although manufacturers such as Novo Nordisk are doing their best to increase supply, these drugs have been facing intermittent shortages over the past year.
However, affordability remains a challenge, and spending $1000 per month is indeed too expensive. Approximately 54% of people taking GLP-1 medication find it difficult to afford even with insurance.
For most Americans, the actual price they pay for their medication depends on their healthcare insurance policies, rather than the prices listed by pharmaceutical companies. However, many medical insurance providers are unwilling to cover GLP-1 drugs, and state public medical assistance in the United States does not reimburse weight loss, but many states support the use of Ozempic to treat diabetes.
Initiate an investigation
In fact, after calling for a price reduction in Novo Nordisk earlier was ineffective, Sanders' Senate Health Committee had already launched an investigation into Novo Nordisk's pricing at the end of April.
Sanders previously sent a message to the CEO of Cignano and Nordisk, saying that the drugs developed by the company are highly commendable and may change the public health crisis facing the United States, that is, the widespread prevalence of obesity and diabetes.
The letter also mentioned, "Although these drugs are important, they have no benefits for millions of patients who cannot afford them. In addition, if the prices of these drugs do not significantly decrease, they may also bankrupt the entire healthcare system in the United States."
Sanders asked Novo Nordisk to answer whether they would "significantly reduce" the prices of these drugs and provide information on how much money was earned from selling these drugs, how much money was spent on research and development, and how they were priced.
In addition, Sanders pointed out that the single box production cost of drugs such as Ozempic is less than $5, and there are pricing issues with drugs in the United States. Ozempic is priced close to $969 in the United States, $155 in Canada, and $59 in Germany. Wegovy is priced at $1349 in the US, $140 in Germany, and $92 in the UK.
Novo Nordisk responded by stating that the company agrees with Sanders' view that obtaining medication is important for patients. And it stated that the company is still committed to working with policy makers to promote solutions and support all patients to have access to and afford medication.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  •   知名做空机构香橼研究(Citron Research)周四(11月21日)在社交媒体平台X上发布消息称,该公司已决定做空“比特币大户”微策略(Microstrategy)这家公司,并认为该公司已经将自己变身成为一家比特币投资基金 ...
    caffycat
    昨天 11:18
    支持
    反对
    回复
    收藏
  •   每经AI快讯,11月20日,文远知行宣布旗下自动驾驶环卫车S6与无人扫路机S1分别在新加坡滨海湾海岸大道与滨海艺术中心正式投入运营。据介绍,这是新加坡首个商业化运营的自动驾驶环卫项目。 ...
    star8699
    3 天前
    支持
    反对
    回复
    收藏
  •   上证报中国证券网讯(记者王子霖)11月20日,斗鱼发布2024年第三季度未经审计的财务报告。本季度斗鱼依托丰富的游戏内容生态,充分发挥主播资源和新业务潜力,持续为用户提供高质量的直播内容及游戏服务,进一步 ...
    goodfriendboy
    3 天前
    支持
    反对
    回复
    收藏
  •   人民网北京11月22日电 (记者栗翘楚、任妍)2024广州车展,在新能源汽车占据“半壁江山”的同时,正加速向智能网联新能源汽车全面过渡,随着“端到端”成为新宠,智能驾驶解决方案成为本届广州车展各大车企竞 ...
    3233340
    昨天 17:06
    支持
    反对
    回复
    收藏
王俊杰2017 注册会员
  • 粉丝

    0

  • 关注

    0

  • 主题

    28